Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HMR1766 vs placebo vs cilostazol in intermittent claudication (Fontaine II PAD)
2006-004275-35Phase 2Completed
- Sponsor
- Sanofi
- Start
- Jan 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ataciguat in arteriosclerosis obliterans and intermittent claudication (IC) (5 arms), sponsored by Sanofi. Started Jan 2007; status: completed.
02
Drugs
ataciguat
03
Conditions
arteriosclerosis obliteransintermittent claudication (IC)
Beyond the preview
Go deeper on 2006-004275-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-004275-35.